ERBB2 and breast carcinoma: For instance, loss of PTEN in a HER2-overexpression genetic background or the trastuzumab resistance in breast cancer cells has been linked to activation of the IL-6/STAT-3/NF-κB inflammatory loop, which induced an EMT phenotype and expansion of the CSC population.